Nano-graphene oxide-mediated In vivo fluorescence imaging and bimodal photodynamic and photothermal destruction of tumors.
Cancer is one of the major life-threatening diseases among human beings. Developing a simple, cost-effective and biocompatible approach to treat cancers using ultra-low doses of light is a grand challenge in clinical cancer treatments. In this study, we report for the first time that nano-sized graphene oxide (GO) exhibits single-photon excitation wavelength dependent photoluminescence in the visible and short near-infrared (NIR) region, suitable for in vivo multi-color fluorescence imaging. We also demonstrate in both in vitro and in vivo experiments to show that nano GO can sensitize the formation of singlet oxygen to exert combined nanomaterial-mediated photodynamic therapeutic (NmPDT) and photothermal therapy (NmPTT) effects on the destruction of B16F0 melanoma tumors in mice using ultra-low doses (∼0.36 W/cm(2)) of NIR (980 nm) light. The average half-life span of the mice treated by the GO-PEG-folate-mediated NmPDT effects is beyond 30 days, which is ∼1.8 times longer than the mice treated with doxorubicin (17 days). Overall, the current study points out a successful example of using GO-PEG-folate nanocomposite as a theranostic nanomedicine to exert simultaneously in vivo fluorescent imaging as well as combined NmPDT and NmPTT effects for clinical cancer treatments.
Department of Chemistry, National Tsing Hua University, Hsinchu, 30013, Taiwan, ROC.
Poliraju
P
Kalluru
Department of Chemistry, National Tsing Hua University, Hsinchu, 30013, Taiwan, ROC.
Raviraj
R
Vankayala
Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu, 30013, Taiwan, ROC.
Chi-Shiun
CS
Chiang
Department of Chemistry, National Tsing Hua University, Hsinchu, 30013, Taiwan, ROC. Electronic address: kchwang@mx.nthu.edu.tw.
Kuo Chu
KC
Hwang
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D045744:Cell Line, Tumor; D004317:Doxorubicin / Q000627:therapeutic use; D005492:Folic Acid / Q000031:analogs & derivatives / Q000737:chemistry; D006108:Graphite / Q000737:chemistry* / Q000627:therapeutic use; D006207:Half-Life; D006801:Humans; D007834:Lasers; D008027:Light; D008297:Male; D008546:Melanoma, Experimental / Q000000981:diagnostic imaging / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D053761:Nanocomposites / Q000737:chemistry* / Q000627:therapeutic use; D061848:Optical Imaging; D010087:Oxides / Q000737:chemistry* / Q000627:therapeutic use; D010778:Photochemotherapy; D010789:Phototherapy; D011092:Polyethylene Glycols / Q000737:chemistry; D026082:Singlet Oxygen / Q000378:metabolism; D012878:Skin Neoplasms / Q000000981:diagnostic imaging / Q000628:therapy*
D000970:Antineoplastic Agents; D010087:Oxides; C552831:poly(ethylene glycol)-folate; D026082:Singlet Oxygen; D011092:Polyethylene Glycols; D006108:Graphite; D004317:Doxorubicin; D005492:Folic Acid
Graphene oxide; Near infra-red light; Photodynamic therapy; Photoluminescence; Photothermal therapy; Singlet oxygen